The Additional Hetero Ring Consists Of Carbon And Chalcogen As The Only Ring Members Patents (Class 514/266.24)
-
Publication number: 20110118258Abstract: Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.Type: ApplicationFiled: May 15, 2008Publication date: May 19, 2011Inventors: Stephen Martin Courtney, Mark Whittaker, Owen Clifford Mather, Christopher John Yarnold, Oliver Robin Barker, Christian Aldo Georges Napoleon Montalbetti, Thomas Hesterkamp, Mihaly Daniel Gardiner
-
Publication number: 20110118245Abstract: Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O)t; Ra is O or S.Type: ApplicationFiled: March 17, 2009Publication date: May 19, 2011Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
-
Publication number: 20110110933Abstract: The invention pertains to methods for treating ectopic pregnancy. More particularly, the present invention relates to methods for treating unruptured ectopic pregnancy using a non-surgical method comprising the administration of an EGFR inhibitor alone or in combination with an anti-metabolite e.g. methotrexate (MTX). The methodology is potentially applicable to treatment of unruptured ectopic pregnancies of all sizes.Type: ApplicationFiled: October 1, 2010Publication date: May 12, 2011Applicant: Monash UniversityInventors: STEPHEN TONG, Ulrika W. Nilsson, Terence Grant Johns
-
Publication number: 20110104249Abstract: The subject invention concerns materials and methods for treating oncological disorders in a person or animal using any agent or compound that inhibits uptake of glucose into a cell. The subject invention also concerns methods for inducing apoptosis and inhibiting the proliferation or survival of a cell. In one embodiment, the methods comprise administering an effective amount of an agent or compound that inhibits the activity of one or more glucose transporter proteins, such as Glut-1. An antibody that binds to and inhibits a glucose transporter protein can be used in the present methods.Type: ApplicationFiled: August 15, 2008Publication date: May 5, 2011Applicant: University of South FloridaInventor: George R. Simon
-
Publication number: 20110098247Abstract: Compounds of formula I are provided: wherein Ar1 and Ar2 are substituted aromatic rings and L1 and L2 are independent divalent linking groups. The compounds are useful as platelet ADP receptor inhibitors, for treating thrombosis and for reducing the likelihood and/or severity of a secondary ischemic event in a patient.Type: ApplicationFiled: October 26, 2010Publication date: April 28, 2011Applicant: Portola Pharmaceuticals, Inc.Inventors: Robert M. Scarborough, Shawn M. Bauer, Anjali Pandey, Carrol Anna Crew Scarborough
-
Publication number: 20110097320Abstract: This invention relates to novel 4-aminoquinazolines, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of the EGFR and HER-2.Type: ApplicationFiled: September 2, 2010Publication date: April 28, 2011Applicant: CoNCERT Pharmaceuticals Inc.Inventor: Roger TUNG
-
Publication number: 20110092524Abstract: The invention relates to a pharmacological action of a compound which functions as a PPAR? agonist on the barrier function of the corneal epithelium. A PPAR? agonist such as rivoglitazone, DRF-2593, GW-544 or BMS-298585 exhibits an excellent effect of enhancing the corneal epithelial barrier function in a test for enhancement of corneal epithelial barrier function, and therefore is useful as a preventive agent or a therapeutic agent for ocular infection or ocular unidentified complaint caused by a decrease in the corneal epithelial barrier function. Further, the PPAR? agonist can enhance the corneal epithelial barrier function of diabetic patients, patients with decreased corneal epithelial barrier function due to aging and patients who underwent refractive surgery such as PRK (photorefractive keratectomy) or LASIK (laser in situ keratomileusis) or cataract surgery.Type: ApplicationFiled: February 25, 2009Publication date: April 21, 2011Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Shin-ichiro Hirai, Atsushi Yoshida
-
Publication number: 20110086817Abstract: Embodiments herein provide compounds and methods of making and using such compounds for prevention and treatment of multidrug resistant bacteria. In particular, embodiments are directed to anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria.Type: ApplicationFiled: May 29, 2009Publication date: April 14, 2011Applicant: University of Notre Dame du LacInventors: Marvin J. Miller, Garrett C. Moraski
-
Publication number: 20110086039Abstract: This invention relates generally to a therapeutic use of epidermal growth factor receptor inhibitors to reduce fibrosis, e.g., liver fibrosis, or pre-cirrhosis in a subject.Type: ApplicationFiled: October 8, 2010Publication date: April 14, 2011Applicant: GENERAL HOSPITAL CORPORATION, THEInventors: Kenneth Tanabe, Bryan C. Fuchs
-
Publication number: 20110077246Abstract: The present invention relates methods for treating disease conditions selected from the list consisting of benign or malignant tumors, diseases of the airways and lungs, diseases of the gastrointestinal tract, the bile duct and the gall bladder by administration to a patient in need thereof of a therapeutically effective amount of a bicyclic heterocyclic groups of general formula wherein said substituents are as defined herein.Type: ApplicationFiled: December 6, 2010Publication date: March 31, 2011Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO.Inventors: Frank HIMMELSBACH, Birgit JUNG, Flavio SOLCA
-
Publication number: 20110071169Abstract: The present invention is directed to two novel polymorph form (Form A and Form B) of lapatinib ditosylate, wherein Form A is the hydrate ditosylate salt of lapatinib, and Form B is anhydrate ditosylate salt of lapatinib. The present invention is further directed to amorphous form of lapatinib ditosylate and its solid dispersion. The present invention further provides processes for the preparation of Form A, Form B, Amorphous form and solid dispersion of lapatinib ditosyalte, and a pharmaceutical composition comprising the said forms. Form A and Form B were characterized by X-RPD, DSC, TGA and FT-IR, and can be prepared from recrystallizing lapatinib ditosylate in a mixture of tetrahydrofuran (THF) and water.Type: ApplicationFiled: August 14, 2010Publication date: March 24, 2011Inventors: Hui Min He Huang, Hu Yang
-
Publication number: 20110071144Abstract: The invention relates to quinazoline derivatives of formula (1) wherein m is an integer from 1 to 2; R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR5R6 (wherein R5 and R6, which may be the same or different, each represents hydrogen or C1-3alkyl); R2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R3 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X1 represents —O—, —CH2—, —S—, —SO—, —SO2—, —NR7CO—, —CONR8—, —SO2NR9—, —NR10SO2— or —NR11— (wherein R7, R8, R9, R10 and R11 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl); R4 represents an optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group or a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted group seleType: ApplicationFiled: April 23, 2010Publication date: March 24, 2011Inventors: Andrew Peter THOMAS, Craig Johnstone, Edward Clayton, Elaine Sophie Elizabeth Stokes, Jean-Jacques Marcel Lohmann, Laurent Francois Andre Hennequin
-
Publication number: 20110059076Abstract: Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate.Type: ApplicationFiled: April 9, 2010Publication date: March 10, 2011Inventors: Charlotte McDonagh, Michael Feldhaus, Alexandra Huhalov
-
Publication number: 20110053964Abstract: This invention relates to novel 4-aminoquinazolines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of the EGFR and HER-2.Type: ApplicationFiled: September 10, 2010Publication date: March 3, 2011Inventors: Roger Tung, Adam J. Morgan
-
Publication number: 20110046168Abstract: A compound of general formula I wherein: Ra is a benzyl, 1-phenylethyl, or 3-chloro-4-fluorophenyl group; Rb is a dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and Rc is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a tautomer, stereoisomer, or salt thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction medType: ApplicationFiled: October 28, 2010Publication date: February 24, 2011Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Frank HIMMELSBACH, Elke LANGKOPF, Stefan BLECH, Birgit JUNG, Anke BAUM, Flavio SOLCA
-
Publication number: 20110033459Abstract: The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, for the treatment of thrombosis diseases.Type: ApplicationFiled: October 20, 2010Publication date: February 10, 2011Inventors: Pamela B. Conley, Patrick Andre, Uma Sinha
-
Publication number: 20110028433Abstract: The present invention provides compounds of formula (I), their use as inhibitors of tubulin polymerization as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, n, m and X have defined meanings.Type: ApplicationFiled: March 26, 2009Publication date: February 3, 2011Applicants: JANSSEN PHARMACEUTICA NV, JANSSEN-CILAGInventors: Eddy Jean Edgard Freyne, Laurence Anne Mevellec, Jorge Eduardo Vialard, Christophe Meyer, Elisabeth Thérèse Jeanne Pasquier, Xavier Marc Bourdrez, Patrick René Angibaud
-
Publication number: 20110028499Abstract: It is found that compounds having PPAR? agonistic activity induced abnormal blood coagulation or muscular disorder. A pharmaceutical combination comprising vitamin K and a compound having PPAR? agonistic activity can prevent the abnormal blood coagulation. A pharmaceutical composition comprising vitamin K can prevent muscular disorder.Type: ApplicationFiled: September 30, 2010Publication date: February 3, 2011Applicant: SHIONOGI & CO., LTD.Inventors: Satoshi INOUE, Seiji SATO, Yoshimasa KYOKAWA, Ken-ichi SUGITA, Mikinori TORII
-
Publication number: 20110020335Abstract: The truncated ErbB2 receptor (p95ErbB2) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95ErbB2 heterodimerization with ErbB3, it is shown that heregulin (an ErbB3 ligand) stimulates p95ErbB2 phosphorylation in breast cancer cell lines. Described herein are methods of identifying patients suitable for treatment with a p95ErbB2 inhibitor, and methods of treating such patients.Type: ApplicationFiled: September 30, 2010Publication date: January 27, 2011Inventors: Neil Lee Spector, Wenle Xia
-
Publication number: 20110020217Abstract: There is described a pharmaceutical composition comprising dexanabinol, or a derivative thereof, in combination with a second therapeutic agent that targets BRAF or MEK, and a pharmaceutically acceptable adjuvant, diluent or carrier. There is also described a method of treating a patient suffering from melanoma and uses related thereto.Type: ApplicationFiled: October 10, 2008Publication date: January 27, 2011Applicant: E-THERAPEUTICS PLCInventors: Malcolm Philip Young, Catherine Mary Thomas, Olusola Clement Idowu
-
Publication number: 20110021495Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: ApplicationFiled: January 15, 2010Publication date: January 27, 2011Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Jesus Gonzalez, III, Dean Wilson, Andreas Termin, Peter D. J. Grootenhuis, Yulian Zhang, Benjamin Petzoldt, Lev T.D. Fanning, Timothy Neubert, Roger Tung, Esther Martinborough, Nicole Hilgraf
-
Publication number: 20110009436Abstract: The disclosure relates to methods of using an adrenergic ?-1 receptor antagonist or its pharmaceutically acceptable salts for treating and/or preventing interstitial cystitis, overactive bladder or detrusor overactivity.Type: ApplicationFiled: March 24, 2010Publication date: January 13, 2011Applicant: SANOFI-AVENTISInventor: Pierangelo GEPPETTI
-
Publication number: 20110009435Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable salts thereof, processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as anti-inflammatory agents.Type: ApplicationFiled: May 19, 2008Publication date: January 13, 2011Applicant: Pfizer, Inc.Inventors: Mark E. Schnute, Peter G. Ruminski, Cathleen E. Hanau, Joseph W. Stobach, Jeffery Carroll, Kirby Sample
-
Publication number: 20110003789Abstract: The invention relates to antibacterial compounds of formula I wherein one or two of U, V, W, and X represent N, the rest represent CH or, in the case of X, may also represent CRa wherein Ra is fluorine; R1 represents alkoxy, halogen or cyano; R2 represents H, CH2OH, CH2N3, CH2NH2, alkylcarbonylaminomethyl or triazol-1-ylmethyl; R3 represents H, or, when n is 1, R3 may also represent OH, NH2, NHCOR6 or triazol-1-yl; A represents CR4; K represents O, NH, OCH2, NHCO, NHCH2, CH2NH, CH2CH2, CH?CH, CHOHCHOH or CHR5; R4 represents H or together with R5 forms a bond, or also R4 can represent OH when K is not O, NH, OCH2 or NHCO; R5 represents OH or together with R4 forms a bond; R6 represents alkyl; m is 0 or 1 and n is 0 or 1; and G is as defined in the description; and to salts of such compounds.Type: ApplicationFiled: December 17, 2008Publication date: January 6, 2011Inventors: Christian Hubschwerlen, Georg Rueedi, Jean-Philippe Surivet, Cornelia Zumbrunn Acklin
-
Publication number: 20100332417Abstract: The present disclosure relates generally to methods for the detection and quantitation of the p95 component of HER2/neu (ERbB2). Such methods may comprise assaying the biological sample for expression of HER2 ICD; assaying the biological sample for expression of a HER2 ECD; quantitating an expressed amount of the HER2 ICD and an expressed amount of the HER2 ECD in the biological sample; and determining the amount of p95 expressed in the biological sample based on a difference between the expressed amount of the HER2 ICD and the expressed amount of the HER2 ECD. The methods of the present disclosure may be used to predict whether a subject will be responsive to a receptor tyrosine kinase inhibitor and/or may be used to select subjects for inclusion/exclusion in a clinical trial.Type: ApplicationFiled: June 2, 2010Publication date: December 30, 2010Applicant: TARGETED MOLECULAR DIAGNOSTICS, LLCInventor: Sarah S. Bacus
-
Patent number: 7846936Abstract: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.Type: GrantFiled: June 17, 2008Date of Patent: December 7, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Frank Hilberg, Flavio Solca, Anke Baum, Jacobus C. A. van Meel
-
Publication number: 20100305070Abstract: The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. Provided are methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. Finally, provided is a method for determining the efficacy of a compound as described herein in treating cancer.Type: ApplicationFiled: April 30, 2010Publication date: December 2, 2010Applicant: The University Court of the University of DundeeInventors: Steven Albert Everett, Saraj Ulhaq
-
Publication number: 20100303809Abstract: The present disclosure provides methods for determining if PTEN is elevated or reduced in one or more tumor cells relative to one or more normal cells in the same biological sample by obtaining a biological sample comprising one or more tumor cells and one or more normal cells; assaying the biological sample for expression of PTEN; quantitating an amount of PTEN expression in the one or more tumor cells and an amount of PTEN expression in the one or more normal cells; comparing the amount of PTEN expression in the tumor cells to the amount of PTEN expression in the normal cells; and determining that PTEN is elevated in the tumor cells where the amount of expression of PTEN is greater in the tumor cells as compared to the normal cells or determining that PTEN is reduced in the tumor cells where the amount of expression of PTEN is less in the tumor cells than in the normal cells.Type: ApplicationFiled: June 1, 2010Publication date: December 2, 2010Applicant: TARGETED MOLECULAR DIAGNOSTICS, LLCInventor: Sarah S. Bacus
-
Publication number: 20100291025Abstract: The present invention relates to new indazole inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: April 13, 2010Publication date: November 18, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Tadimeti Rao, Chengzhi Zhang
-
Patent number: 7834000Abstract: The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.Type: GrantFiled: June 13, 2007Date of Patent: November 16, 2010Assignee: Vertex Pharmaceuticals IncorporatedInventors: Corey Gutierrez, Andreas Termin, Sara Hadida-Ruah, Pramod Joshi, Daniele Bergeron, Sanghee Yoo, Hayley Binch, Jon Come, Jingrong Cao, Suganthi Nanthakumar
-
Patent number: 7829574Abstract: Substituted quinazoline compounds of the following formula: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and X are defined herein. It also discloses a pharmaceutical composition containing one of these compounds.Type: GrantFiled: May 9, 2008Date of Patent: November 9, 2010Assignee: Hutchison MediPharma Enterprises LimitedInventors: Wei-Guo Su, Weihan Zhang, Xiaoqiang Yan, Yumin Cui, Yongxin Ren, Jifeng Duan
-
Publication number: 20100279971Abstract: This invention relates to compounds of the formula X) or XI) (X) (XI) wherein: each —R1, —R2 and —R3 is independently -Q1, —OH or —H, where at least one of —R1, —R2 and —R3 is not —H or —OH; each —R4 and —R5 is independently -Q2 or —H; each -Q1 is independently selected from: —F, —Cl, —RA, —ORA, —SH, —SRA, where each —RA is independently selected from methyl and ethyl, which may substituted by one or more fluoro or chloro groups; and each -Q2 is selected from: —F, —Cl, —RB, —ORB, —SH, —SRB, where each —RB is independently selected from methyl and ethyl, which may substituted by one or more fluoro or chloro groups; which are useful in the treatment of melanoma.Type: ApplicationFiled: December 18, 2008Publication date: November 4, 2010Inventors: Jose Neptuno Rodriguez-Lopez, Luis Sanchez Del Campo Ferrer, Juan Cabezas-Herrera, Alberto Tarraga Tomas, Magali Maria Saez Ayala
-
Publication number: 20100267633Abstract: The invention relates to substituted N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamid derivatives which modulate androgen receptors to treat conditions such as: osteoporosis, peridontal disease, bone fracture, frailty, and sarcopenia.Type: ApplicationFiled: September 22, 2006Publication date: October 21, 2010Inventors: Barbara Hanney, Yuntae Kim, Helen J. Mitchell, Jeffrey D. Musselman, James J. Perkins
-
Publication number: 20100260674Abstract: This invention relates to novel quinazoline derivatives, and their pharmaceutically acceptable salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibiting cell surface tyrosine receptor kinases.Type: ApplicationFiled: January 26, 2010Publication date: October 14, 2010Applicant: Concert Pharmaceuticals, Inc.Inventor: Roger Tung
-
Publication number: 20100260753Abstract: Disclosed are methods of treating breast cancer by administering to a mammal aminoflavone, and optionally one or more additional anti-cancer agents. According to example embodiments, the methods include methods of treating cancers resistant to endocrine therapy.Type: ApplicationFiled: October 22, 2008Publication date: October 14, 2010Inventors: Angelika Burger, Edward Sausville, Phillip Shelton
-
Publication number: 20100249160Abstract: A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.Type: ApplicationFiled: June 15, 2010Publication date: September 30, 2010Inventors: Karen Elizabeth Lackey, Robert J. Mullin, Neil Spector, Edgar Raymond Wood, III, Wenie Xia
-
Publication number: 20100239656Abstract: Compositions and methods for the treatment and diagnosis of cancer are disclosed.Type: ApplicationFiled: May 10, 2010Publication date: September 23, 2010Inventors: Igor Astsaturov, Erica A. Golemis, Ilya G. Serebriiskii, Louis M. Weiner
-
Publication number: 20100241219Abstract: An adjunctive accessory article (25) for controlled release of at least a single physiologically active agent form an indwelling medical device so equipped is provided. The article is configurable as a tubular element upon a portion of the indwelling medical device, with barriers or facilitating coverings overlaying the carrier in furtherance of the controlled release of the active agent. To the extent that requires, affixation means for stable placement upon an indwelling device are further contemplated. Finally, a variety of application systems are described in connection to deployment of sleeve articles upon a portion of an indwelling device.Type: ApplicationFiled: June 20, 2006Publication date: September 23, 2010Applicant: ABBEYMOOR MEDICAL , INCInventors: Lloyd K. Willard, Mark J. Whalen, John M. Reid, Chad S. Smith, Charles L. Euteneuer, Paul Buscemi
-
Publication number: 20100234350Abstract: Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 14, 2009Publication date: September 16, 2010Applicant: Portola Pharmaceuticals, Inc.Inventors: Robert M. Scarborough, Wolin Huang, Charles K. Marlowe, Kim A. Kane-McGuire, Hans-Michael Jantzen, David M. Sedlock
-
Publication number: 20100222344Abstract: A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.Type: ApplicationFiled: November 29, 2006Publication date: September 2, 2010Inventor: Bernard Christophe Barlaam
-
Publication number: 20100196358Abstract: The present invention is related to a method and kit (or device) for the detection and/or the quantification of biomarkers related to tumorigenesis. Said method is advantageously used to propose or adapt an anti-tumoral therapeutic protocol to be administered to a subject. Furthermore, said method and kit (or device) are a technical platform for the identification of new compounds, which are preferably used at (a) specific step(s) of an anti-tumoral therapeutic protocol.Type: ApplicationFiled: February 16, 2006Publication date: August 5, 2010Applicant: Eppendorf Array Technologies S.A.Inventors: Veronique Mainfroid, Jose Remacle
-
Publication number: 20100190694Abstract: The invention provides methods for identifying patients who will respond well to cancer treatment with a therapeutic regimen that comprises the use of a histone deacetylase inhibitor (HDACi) and one or more further chemotherapeutic agents. The invention also relates to methods of treating such patients with a therapeutic regimen comprising the use of a histone deacetylase inhibitor (HDACi) and one or more further chemotherapeutic agents.Type: ApplicationFiled: January 14, 2010Publication date: July 29, 2010Inventor: Jan Fagerberg
-
Publication number: 20100183717Abstract: Disclosed herein are controlled-release formulations of a core comprising a core active agent (e.g., alfuzosin) and a wax excipient substantially coated with an extended-release coating.Type: ApplicationFiled: January 15, 2010Publication date: July 22, 2010Inventors: Kristin Arnold, Zhongshui Yu, Siva Rama K. Nutalapati
-
Publication number: 20100183593Abstract: The invention provides compositions and methods for determining the likelihood of successful treatment with dual therapy such as lapatinib. The methods comprise determining the genomic polymorphism or expression level of a gene present in a predetermined region of a gene of interest and correlating the polymorphism or expression level to the predictive response. Patients identified as likely responsive are then treated with the appropriate therapy.Type: ApplicationFiled: January 17, 2008Publication date: July 22, 2010Applicant: University of Southern CaliforniaInventor: Heinz-Josef Lenz
-
Publication number: 20100183604Abstract: The present invention provides an agent for preventing or treating a trastuzumab-resistant cancer, which contains one or more medicaments selected from a cofilin inhibitor, a PAK1 inhibitor, a LIMK inhibitor, a RHO inhibitor, a ROCK1 inhibitor and a ROCK2 inhibitor.Type: ApplicationFiled: June 19, 2008Publication date: July 22, 2010Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yoshikazu Ohta, Akira Hayashi
-
Publication number: 20100173013Abstract: The present application is generally directed to compounds, compositions and methods of combination therapy for the treatment of neoplastic disorders.Type: ApplicationFiled: January 7, 2010Publication date: July 8, 2010Inventors: Denis Drygin, Kenna Anderes, Caroline B. Ho, Joshua R. Bliesath, Christopher B. Proffitt, Sean O'Brien, William G. Rice
-
Publication number: 20100173918Abstract: The present disclosure relates to a method, kit and controls for detecting phosphorylated Tyr1248 in the c-erbB-2 protein as a predictor of breast cancer progression and as a predictor of therapeutic efficacy of drugs that inhibit both epidermal growth factor receptor and erbB2 protein kinases.Type: ApplicationFiled: February 28, 2008Publication date: July 8, 2010Applicant: TARGETED MOLECULAR DIAGNOSTICS, LLCInventor: Sarah Bacus
-
Publication number: 20100166765Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof, wherein the groups R2, R3, R4, Q, X and Y are as defined in the specification, is useful in the treatment of bone conditions related to increased calcium depletion or resorption.Type: ApplicationFiled: August 14, 2006Publication date: July 1, 2010Inventors: Sandra Ammon, Rene Beerli, Leo Widler
-
Publication number: 20100151019Abstract: A novel solid composition and methods for making and using the solid composition are provided. The solid composition comprises: (a) at least one active agent with a solubility of less than about 0.3 mg/ml in an aqueous solution with a pH of at most about 6.8 at a temperature of about 37° C.; and (b) a hydrophilic polymer matrix composition comprising: i) a hydrophilic polymer selected from the group consisting of METHOCEL™, POLYOX™ WSR 1105 and combinations thereof; and optionally ii) a hydrophobic polymer selected from the group consisting of Ethocel 20 premium; and (c) an alkalizer selected from the group consisting of calcium carbonate, magnesium oxide heavy and sodium bicarbonate; wherein the composition provides at least about 70% release of the active between about 7 to about 12 hours following oral administration.Type: ApplicationFiled: November 13, 2009Publication date: June 17, 2010Applicant: Portola Pharmaceuticals, Inc.Inventors: Chandir Ramani, Juan Wang, Anil Kane, Kwok Chow, Joe Lambing
-
Publication number: 20100143459Abstract: A pharmaceutical dosage form comprises a solid dispersion product of at least one tyrosine kinase inhibitor, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer.Type: ApplicationFiled: November 8, 2007Publication date: June 10, 2010Applicant: ABBOTT GMBH & CO. KGInventors: Bernd Liepold, Jörg Rosenberg, Martin Knobloch, Christian Nehen